More recently, Choi and colleagues evaluated the cost-effectiveness of SGLT2is and GLP-1RAs, taken individually, as first-line therapies for American patients with T2DM, compared with metformin as first-line therapy
December 15, 2025: Study About the Brain Benefits of Taking Trulicity Shows Modest Connection, Inconclusive Results An observational study explored whether taking Trulicity and other GLP-1s was associated with some brain benefits, like lower risks of epilepsy
At SELF, our job is to present youour readerwith science-backed information that you can use to guide the decisions you make about your body, which is why we wrote the article below
Retrieved from DailyMed
Para pacientes que consideran suspender o reducir el tratamiento con agonistas GLP-1, existen varias estrategias que pueden ayudar a mantener los beneficios obtenidos, aunque la evidencia sobre su efectividad es limitada
Mejora el rendimiento y la resistencia